Exosome nanovesicles: biomarkers and new strategies for treatment of human diseases

Abstract

Exosomes are nanoscale vesicles of cellular origin. One of the main characteristics of exosomes is their ability to carry a wide range of biomolecules from their parental cells, which are important mediators of intercellular communication and play an important role in physiological and pathological processes. Exosomes have the advantages of biocompatibility, low immunogenicity, and wide biodistribution. As researchers’ understanding of exosomes has increased, various strategies have been proposed for their use in diagnosing and treating diseases. Here, we provide an overview of the biogenesis and composition of exosomes, describe the relationship between exosomes and disease progression, and focus on the use of exosomes as biomarkers for early screening, disease monitoring, and guiding therapy in refractory diseases such as tumors and neurodegenerative diseases. We also summarize the current applications of exosomes, especially engineered exosomes, for efficient drug delivery, targeted therapies, gene therapies, and immune vaccines. Finally, the current challenges and potential research directions for the clinical application of exosomes are also discussed. In conclusion, exosomes, as an emerging molecule that can be used in the diagnosis and treatment of diseases, combined with multidisciplinary innovative solutions, will play an important role in clinical applications.

Keywords

drug delivery / exosome / immunotherapy / liquid biopsy / targeted therapies

References

[1] van Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018; 19(4): 213-228.

[2] Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9(6): 654-659.

[3] Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018; 7(1): 1535750.

[4] Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014; 30: 255-289.

[5] Peng LH, Wang MZ, Chu Y, et al. Engineering bacterial outer membrane vesicles as transdermal nanoplatforms for photo-TRAIL-programmed therapy against melanoma. Sci Adv. 2020; 6(27): eaba2735.

[6] Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013; 200(4): 373-383.

[7] Iraci N, Leonardi T, Gessler F, Vega B, Pluchino S. Focus on extracellular vesicles: physiological role and signalling properties of extracellular membrane vesicles. Int J Mol Sci. 2016; 17(2): 171.

[8] Biller SJ, Schubotz F, Roggensack SE, Thompson AW, Summons RE, Chisholm SW. Bacterial vesicles in marine ecosystems. Science. 2014; 343(6167): 183-186.

[9] Cai Q, Qiao L, Wang M, et al. Plants send small RNAs in extracellular vesicles to fungal pathogen to silence virulence genes. Science. 2018; 360(6393): 1126-1129.

[10] Street JM, Barran PE, Mackay CL, et al. Identification and proteomic profiling of exosomes in human cerebrospinal fluid.pdf. J Transl Med. 2012; 10: 5.

[11] Choi DS, Kim DK, Kim YK, Gho YS. Proteomics, transcriptomics and lipidomics of exosomes and ectosomes. Proteomics. 2013; 13(10-11): 1554-1571.

[12] Gangoda L, Boukouris S, Liem M, Kalra H, Mathivanan S. Extracellular vesicles including exosomes are mediators of signal transduction: are they protective or pathogenic? Proteomics. 2015; 15(0): 260-271.

[13] Skriner K, Adolph K, Jungblut PR, Burmester GR. Association of citrullinated proteins with synovial exosomes. Arthritis Rheum. 2006; 54(12): 3809-3814.

[14] Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int. 2010; 78(9): 838-848.

[15] Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J Proteomics. 2010; 73(10): 1907-1920.

[16] Becker A, Thakur BK, Weiss JM, et al. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell. 2016; 30(6): 836-848.

[17] Yu D, Li Y, Wang M, et al. Exosomes as a new frontier of cancer liquid biopsy. Mol Cancer. 2022; 21(1): 56.

[18] Street JM, Barran PE, Mackay CL, et al. Identification and proteomic profiling of exosomes in human cerebrospinal fluid. J Transl Med. 2012; 10: 5.

[19] Admyre C, Grunewald J, Thyberg J, et al. Exosomes with major histocompatibility complex class II and co-stimulatory molecules are present in human BAL fluid. Eur Respir J. 2003; 22(4): 578-583.

[20] Ma X, Yang R, Li H, et al. Role of exosomes in the communication and treatment between OSCC and normal cells. Heliyon. 2024; 10(7): e28148.

[21] Lässer C, Alikhani VS, Ekström K, et al. Human saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages. J Transl Med. 2011; 9: 9.

[22] Wang CB, Chen SH, Zhao L, et al. Urine-derived exosomal PSMA is a promising diagnostic biomarker for the detection of prostate cancer on initial biopsy. Clin Transl Oncol. 2023; 25(3): 758-767.

[23] Pan W, Xu X, Zhang M, et al. Human urine-derived stem cell-derived exosomal miR-21-5p promotes neurogenesis to attenuate Rett syndrome via the EPha4/TEK axis. Lab Invest. 2021; 101(7): 824-836.

[24] Palanisamy V, Sharma S, Deshpande A, et al. Nanostructural and transcriptomic analyses of human saliva derived exosomes. PLoS One. 2010; 5(1): e8577.

[25] Poliakov A, Spilman M, Dokland T, et al. Structural heterogeneity and protein composition of exosome-like vesicles (prostasomes) in human semen. Prostate. 2009; 69(2): 159-167.

[26] Mobarak H, Heidarpour M, Rahbarghazi R, et al. Amniotic fluid-derived exosomes improved spermatogenesis in a rat model of azoospermia. Life Sci. 2021; 274: 119336.

[27] Andre F, Schartz NEC, Movassagh M, et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet. 2002; 360(9329): 295-305.

[28] Kalluri R. The biology and function of exosomes in cancer. J Clin Invest. 2016; 126(4): 1208-1215.

[29] Sohal IS, Kasinski AL. Emerging diversity in extracellular vesicles and their roles in cancer. Front Oncol. 2023; 13: 1167717.

[30] Basthi Mohan P, Rajpurohit S, Musunuri B, et al. Exosomes in chronic liver disease. Clin Chim Acta. 2023; 540: 117215.

[31] Moghassemi S, Dadashzadeh A, Sousa MJ, et al. Extracellular vesicles in nanomedicine and regenerative medicine: a review over the last decade. Bioact Mater. 2024; 36: 126-156.

[32] Luo H, Zhang H, Mao J, et al. Exosome-based nanoimmunotherapy targeting TAMs, a promising strategy for glioma. Cell Death Dis. 2023; 14(4): 235.

[33] Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol. 2012; 6(2): 140-146.

[34] Hartwell L, Mankoff D, Paulovich A, et al. Cancer biomarkers: a systems approach. Nat Biotechnol. 2006; 24(8): 905-908.

[35] Alotaibi F. Exosomal microRNAs in cancer: potential biomarkers and immunotherapeutic targets for immune checkpoint molecules. Front Genet. 2023; 14: 1052731.

[36] Hu S, Feng L, Yang Z, et al. A recognition of exosomes as regulators of epigenetic mechanisms in central nervous system diseases. Front Mol Neurosci. 2024; 17: 1370449.

[37] Chen JJ, Yang G, Yan QQ, et al. Exosome-encapsulated microRNAs as promising biomarkers for Alzheimer’s disease. Rev Neurosci. 2019; 31(1): 77-87.

[38] Chen JJ, Zhao B, Zhao J, et al. Potential roles of exosomal microRNAs as diagnostic biomarkers and therapeutic application in Alzheimer’s disease. Neural Plast. 2017; 2017: 7027380.

[39] Tang X, Guo J, Qi F, et al. Role of non-coding RNAs and exosomal non-coding RNAs in vasculitis: a narrative review. Int J Biol Macromol. 2024; 261(2): 129658.

[40] Tan PPS, Hall D, Chilian WM, et al. Exosomal microRNAs in the development of essential hypertension and its potential as biomarkers. Am J Physiol Heart Circ Physiol. 2021; 320(4): H1486-H1497.

[41] Zhang D, Zhao X, Wang B, et al. Identification of serum exosomal miRNA biomarkers for diagnosis of rheumatoid arthritis. Medicine (Baltimore). 2023; 102(30): e34474.

[42] Tsoneva DK, Ivanov MN, Vinciguerra M. Liquid liver biopsy for disease diagnosis and prognosis. J Clin Transl Hepatol. 2023; 11(7): 1520-1541.

[43] Muñoz-Hernández R, Rojas Á, Gato S, et al. Extracellular vesicles as biomarkers in liver disease. Int J Mol Sci. 2022; 23(24): 16217.

[44] Mimmi S, Zimbo AM, Rotundo S, et al. SARS CoV-2 spike protein-guided exosome isolation facilitates detection of potential miRNA biomarkers in COVID-19 infections. Clin Chem Lab Med. 2023; 61(8): 1518-1524.

[45] Caobi A, Werne R, Gomez M, et al. Protein cargo of Nef-containing exosomal extracellular vesicles may predict HIV-associated neurocognitive impairment status. Res Sq. Published online June 23, 2023:rs.3.rs-2740135.

[46] Mirzaei R, Babakhani S, Ajorloo P, et al. The emerging role of exosomal miRNAs as a diagnostic and therapeutic biomarker in Mycobacterium tuberculosis infection. Mol Med. 2021; 27(1): 34.

[47] Gong J, Zhang X, Khan A, et al. Identification of serum exosomal miRNA biomarkers for diagnosis of rheumatoid arthritis. Int Immunopharmacol. 2024; 129: 111604.

[48] F C, B S, W L, et al. Circulating exosomal microRNAs as biomarkers of lupus nephritis. Front Immunol. 2023; 14: 1326836.

[49] Y M, X H, Y Y, et al. Study of serum exosome miRNA as a biomarker for early onset adult ouclar myastthenia gravis. Gene. 2024; 896.

[50] Y W, Hr D, Lt L, et al. Advances in the study of exosome-derived miRNAs in the pathogenesis, diagnosis, and treatment of systemic lupus erythematosus. Lupus. 2023; 32(13).

[51] Fitts CA, Ji N, Li Y, et al. Exploiting exosomes in cancer liquid biopsies and drug delivery. Adv Healthc Mater. 2019; 8(6): e1801268.

[52] Sugimachi K, Matsumura T, Hirata H, et al. Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation. Br J Cancer. 2015; 112(3): 532-538.

[53] Manterola L, Guruceaga E, Gállego Pérez-Larraya J, et al. A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro Oncol. 2014; 16(4): 520-527.

[54] Zeng Y, Hu S, Luo Y, et al. Exosome cargos as biomarkers for diagnosis and prognosis of hepatocellular carcinoma. Pharmaceutics. 2023; 15(9): 2365.

[55] Kawada T, Shim SR, Quhal F, et al. Diagnostic accuracy of liquid biomarkers for clinically significant prostate cancer detection: a systematic review and diagnostic meta-analysis of multiple thresholds. Eur Urol Oncol. 2023. Published online November 17. S2588-9311(23)00248-1.

[56] Tan H, Hosein PJ. Detection and therapeutic implications of homologous recombination repair deficiency in pancreatic cancer: a narrative review. J Gastrointest Oncol. 2023; 14(5): 2249-2259.

[57] Zhang Y, Ali A, Xie J. Detection of clinically important BRCA gene mutations in ovarian cancer patients using next generation sequencing analysis. Am J Cancer Res. 2023; 13(10): 5005-5020.

[58] Wang Z, Wang Q, Qin F, et al. Exosomes: a promising avenue for cancer diagnosis beyond treatment. Front Cell Dev Biol. 2024; 12: 1344705.

[59] Li H, Yuan Y, Xie Q, et al. Exosomes: potential targets for the diagnosis and treatment of neuropsychiatric disorders. J Transl Med. 2024; 22(1): 115.

[60] Amin S, Massoumi H, Tewari D, et al. Cell type-specific extracellular vesicles and their impact on health and disease. Int J Mol Sci. 2024; 25(5): 2730.

[61] Al-Madhagi H. The landscape of exosomes biogenesis to clinical applications. Int J Nanomed. 2024; 19: 3657-3675.

[62] van den Boorn JG, Schlee M, Coch C, et al. SiRNA delivery with exosome nanoparticles. Nat Biotechnol. 2011; 29(4): 325-326.

[63] Liu CG, Song J, Zhang YQ, et al. MicroRNA-193b is a regulator of amyloid precursor protein in the blood and cerebrospinal fluid derived exosomal microRNA-193b is a biomarker of Alzheimer’s disease. Mol Med Rep. 2014; 10(5): 2395-2400.

[64] Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020; 367(6478): eaau6977.

[65] Ashrafizadeh M, Kumar AP, Aref AR, et al. Exosomes as promising nanostructures in diabetes mellitus: from insulin sensitivity to ameliorating diabetic complications. Int J Nanomed. 2022; 17: 1229-1253.

[66] Trams EG, Lauter CJ, Salem N, et al. Exfoliation of membrane ecto-enzymes in the form of micro-vesicles. Biochim Biophys Acta. 1981; 645(1): 63-70.

[67] Christ L, Raiborg C, Wenzel EM, et al. Cellular functions and molecular mechanisms of the ESCRT membrane-scission machinery. Trends Biochem Sci. 2017; 42(1): 42-56.

[68] Trajkovic K, Hsu C, Chiantia S, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008; 319(5867): 1244-1247.

[69] van Niel G, Charrin S, Simoes S, et al. The tetraspanin CD63 regulates ESCRT-independent and -dependent endosomal sorting during melanogenesis. Dev Cell. 2011; 21(4): 708-721.

[70] Edgar JR, Eden ER, Futter CE. Hrs-and CD63-dependent competing mechanisms make different sized endosomal intraluminal vesicles. Traffic. 2014; 15(2): 197-211.

[71] Kajimoto T, Mohamed NNI, Badawy SMM, et al. Involvement of Gβγ subunits of Gi protein coupled with S1P receptor on multivesicular endosomes in F-actin formation and cargo sorting into exosomes. J Biol Chem. 2018; 293(1): 245-253.

[72] Kajimoto T, Okada T, Miya S, et al. Ongoing activation of sphingosine 1-phosphate receptors mediates maturation of exosomal multivesicular endosomes. Nat Commun. 2013; 4: 2712.

[73] Ghossoub R, Lembo F, Rubio A, et al. Syntenin-ALIX exosome biogenesis and budding into multivesicular bodies are controlled by ARF6 and PLD2. Nat Commun. 2014; 5: 3477.

[74] Zeng A, Li H, Guo L, et al. Prospectively isolated tetraspanin+ neoblasts are adult pluripotent stem cells underlying planaria regeneration. Cell. 2018; 173(7): 1593-1608. e20.

[75] Zimmerman B, Kelly B, McMillan BJ, et al. Crystal structure of a full-length human tetraspanin reveals a cholesterol-binding pocket. Cell. 2016; 167(4): 1041-1051. e11.

[76] Yang Y, Liu XR, Greenberg ZJ, et al. Open conformation of tetraspanins shapes interaction partner networks on cell membranes. EMBO J. 2020; 39(18): e105246.

[77] Hessvik NP, Llorente A. Current knowledge on exosome biogenesis and release. Cell Mol Life Sci. 2018; 75(2): 193-208.

[78] Maas SLN, Breakefield XO, Weaver AM. Extracellular vesicles: unique intercellular delivery vehicles. Trends Cell Biol. 2017; 27(3): 172-188.

[79] Ly NP, Han HS, Kim M, et al. Plant-derived nanovesicles: current understanding and applications for cancer therapy. Bioact Mater. 2022; 22: 365-383.

[80] Vader P, Breakefield XO, Wood MJA. Extracellular vesicles: emerging targets for cancer therapy. Trends Mol Med. 2014; 20(7): 385-393.

[81] Beloribi S, Ristorcelli E, Breuzard G, et al. Exosomal lipids impact notch signaling and induce death of human pancreatic tumoral SOJ-6 cells. PLoS One. 2012; 7(10): e47480.

[82] Beloribi-Djefaflia S, Siret C, Lombardo D. Exosomal lipids induce human pancreatic tumoral MiaPaCa-2 cells resistance through the CXCR4-SDF-1α signaling axis. Oncoscience. 2015; 2(1): 15-30.

[83] Schutters K, Reutelingsperger C. Phosphatidylserine targeting for diagnosis and treatment of human diseases. Apoptosis. 2010; 15(9): 1072-1082.

[84] Boyiadzis M, Whiteside TL. Information transfer by exosomes: a new frontier in hematologic malignancies. Blood Rev. 2015; 29(5): 281-290.

[85] Fayyazpour P, Fayyazpour A, Abbasi K, et al. The role of exosomes in cancer biology by shedding light on their lipid contents. Pathol Res Pract. 2023; 250: 154813.

[86] Crescitelli R, Lässer C, Szabó TG, et al. Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes. J Extracell Vesicles. 2013; 2.

[87] Melo SA, Sugimoto H, O’Connell JT, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014; 26(5): 707-721.

[88] Salido-Guadarrama I, Romero-Cordoba S, Peralta-Zaragoza O, et al. MicroRNAs transported by exosomes in body fluids as mediators of intercellular communication in cancer. Onco Targets Ther. 2014; 7: 1327-1338.

[89] Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature. 2010; 467(7311): 86-90.

[90] Kahlert C, Melo SA, Protopopov A, et al. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem. 2014; 289(7): 3869-3875.

[91] Sall IM, Flaviu TA. Plant and mammalian-derived extracellular vesicles: a new therapeutic approach for the future. Front Bioeng Biotechnol. 2023; 11: 1215650.

[92] Kowal J, Arras G, Colombo M, et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci USA. 2016; 113(8): E968-E977.

[93] Shang Z, Wanyan P, Wang M, et al. Stem cell-derived exosomes for traumatic spinal cord injury: a systematic review and network meta-analysis based on a rat model. Cytotherapy. 2024; 26(1): 1-10.

[94] Luo M, Luan X, Jiang G, et al. The dual effects of exosomes on glioma: a comprehensive review. J Cancer. 2023; 14(14): 2707-2719.

[95] Altıntaş Ö, Saylan Y. Exploring the versatility of exosomes: a review on isolation, characterization, detection methods, and diverse applications. Anal Chem. 2023; 95(44): 16029-16048.

[96] Graner MW, Alzate O, Dechkovskaia AM, et al. Proteomic and immunologic analyses of brain tumor exosomes. FASEB J. 2009; 23(5): 1541-1557.

[97] Al-Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol. 2008; 10(5): 619-624.

[98] Higginbotham JN, Demory Beckler M, Gephart JD, et al. Amphiregulin exosomes increase cancer cell invasion. Curr Biol. 2011; 21(9): 779-786.

[99] Cao LQ, Yang XW, Chen YB, et al. Exosomal miR-21 regulates the TETs/PTENp1/PTEN pathway to promote hepatocellular carcinoma growth. Mol Cancer. 2019; 18(1): 148.

[100] Gai X, Tang B, Liu F, et al. mTOR/miR-145-regulated exosomal GOLM1 promotes hepatocellular carcinoma through augmented GSK-3β/MMPs. J Genet Genomics. 2019; 46(5): 235-245.

[101] Graner MW, Cumming RI, Bigner DD. The heat shock response and chaperones/heat shock proteins in brain tumors: surface expression, release, and possible immune consequences. J Neurosci. 2007; 27(42): 11214-11227.

[102] Sheng Z, Wang X, Ding X, et al. Exosomal miRNA-92a derived from cancer-associated fibroblasts promote invasion and metastasis in breast cancer by regulating G3BP2. Cell Signal. 2024; 119: 111182.

[103] Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011; 17(11): 1359-1370.

[104] Al-Nedawi K, Meehan B, Kerbel RS, et al. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci USA. 2009; 106(10): 3794-3799.

[105] Skog J, Würdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10(12): 1470-1476.

[106] Feng Q, Zhang C, Lum D, et al. A class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis. Nat Commun. 2017; 8: 14450.

[107] Hegmans JPJJ, Bard MPL, Hemmes A, et al. Proteomic analysis of exosomes secreted by human mesothelioma cells. Am J Pathol. 2004; 164(5): 1807-1815.

[108] Ho HKV, Jang JJ, Kaji S, et al. Developmental endothelial locus-1 (Del-1), a novel angiogenic protein: its role in ischemia. Circulation. 2004; 109(10): 1314-1319.

[109] Théry C, Regnault A, Garin J, et al. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol. 1999; 147(3): 599-610.

[110] Silvestre JS, Théry C, Hamard G, et al. Lactadherin promotes VEGF-dependent neovascularization. Nat Med. 2005; 11(5): 499-506.

[111] Xie M, Yu T, Jing X, et al. Exosomal circSHKBP1 promotes gastric cancer progression via regulating the miR-582-3p/HUR/VEGF axis and suppressing HSP90 degradation. Mol Cancer. 2020; 19(1): 112.

[112] Huang XY, Huang ZL, Huang J, et al. Exosomal circRNA-100338 promotes hepatocellular carcinoma metastasis via enhancing invasiveness and angiogenesis. J Exp Clin Cancer Res. 2020; 39(1): 20.

[113] Conigliaro A, Costa V, Lo Dico A, et al. CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA. Mol Cancer. 2015; 14: 155.

[114] Wang FW, Cao CH, Han K, et al. APC-activated long noncoding RNA inhibits colorectal carcinoma pathogenesis through reduction of exosome production. J Clin Invest. 2019; 129(2): 727-743.

[115] Qiu JJ, Lin XJ, Tang XY, et al. Exosomal metastasis-associated lung adenocarcinoma transcript 1 promotes angiogenesis and predicts poor prognosis in epithelial ovarian cancer. Int J Biol Sci. 2018; 14(14): 1960-1973.

[116] Lei L, Mou Q. Exosomal taurine up-regulated 1 promotes angiogenesis and endothelial cell proliferation in cervical cancer. Cancer Biol Ther. 2020; 21(8): 717-725.

[117] Castellano JJ, Marrades RM, Molins L, et al. Extracellular vesicle lincRNA-p21 expression in tumor-draining pulmonary vein defines prognosis in NSCLC and modulates endothelial cell behavior. Cancers (Basel). 2020; 12(3): 734.

[118] Cheng Y, Dai X, Yang T, et al. Low long noncoding RNA growth arrest-specific transcript 5 expression in the exosomes of lung cancer cells promotes tumor angiogenesis. J Oncol. 2019; 2019: 2476175.

[119] Dai X, Liao K, Zhuang Z, et al. AHIF promotes glioblastoma progression and radioresistance via exosomes. Int J Oncol. 2019; 54(1): 261-270.

[120] Qiu JJ, Lin XJ, Zheng TT, et al. The exosomal long noncoding RNA aHIF is upregulated in serum from patients with endometriosis and promotes angiogenesis in endometriosis. Reprod Sci. 2019; 26(12): 1590-1602.

[121] Ma X, Li Z, Li T, et al. Long non-coding RNA HOTAIR enhances angiogenesis by induction of VEGFA expression in glioma cells and transmission to endothelial cells via glioma cell derived-extracellular vesicles. Am J Transl Res. 2017; 9(11): 5012-5021.

[122] Lang HL, Hu GW, Zhang B, et al. Glioma cells enhance angiogenesis and inhibit endothelial cell apoptosis through the release of exosomes that contain long non-coding RNA CCAT2 - PubMed. Oncol Rep. 2017; 38(2): 785-798.

[123] Lang HL, Hu GW, Chen Y, et al. Glioma cells promote angiogenesis through the release of exosomes containing long non-coding RNA POU3F3. Eur Rev Med Pharmacol Sci. 2017; 21(5): 959-972.

[124] Sruthi TV, Edatt L, Raji GR, et al. Horizontal transfer of miR-23a from hypoxic tumor cell colonies can induce angiogenesis. J Cell Physiol. 2018; 233(4): 3498-3514.

[125] Zeng Z, Li Y, Pan Y, et al. Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. Nat Commun. 2018; 9(1): 5395.

[126] Wang ZF, Liao F, Wu H, et al. Glioma stem cells-derived exosomal miR-26a promotes angiogenesis of microvessel endothelial cells in glioma. J Exp Clin Cancer Res. 2019; 38(1): 201.

[127] Li J, Yuan H, Xu H, et al. Hypoxic cancer-secreted exosomal miR-182-5p promotes glioblastoma angiogenesis by targeting Kruppel-like factor 2 and 4. Mol Cancer Res. 2020; 18(8): 1218-1231.

[128] Nicoli S, Knyphausen CP, Zhu LJ, et al. miR-221 is required for endothelial tip cell behaviors during vascular development. Dev Cell. 2012; 22(2): 418-429.

[129] Liu Y, Luo F, Wang B, et al. STAT3-regulated exosomal miR-21 promotes angiogenesis and is involved in neoplastic processes of transformed human bronchial epithelial cells. Cancer Lett. 2016; 370(1): 125-135.

[130] Cui H, Seubert B, Stahl E, et al. Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes. Oncogene. 2015; 34(28): 3640-3650.

[131] Lu J, Liu QH, Wang F, et al. Exosomal miR-9 inhibits angiogenesis by targeting MDK and regulating PDK/AKT pathway in nasopharyngeal carcinoma. J Exp Clin Cancer Res. 2018; 37(1): 147.

[132] Liu Z, Du D, Zhang S. Tumor-derived exosomal miR-1247-3p promotes angiogenesis in bladder cancer by targeting FOXO1. Cancer Biol Ther. 2024; 25(1): 2290033.

[133] Zhang HG, Grizzle WE. Exosomes. Am J Pathol. 2014; 184(1): 28-41.

[134] Zhou H, Zhu L, Song J, et al. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. Mol Cancer. 2022; 21(1): 86.

[135] Clayton A, Mitchell JP, Court J, et al. Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol. 2008; 180(11): 7249-7258.

[136] Espinoza JL, Takami A, Yoshioka K, et al. Human microRNA-1245 down-regulates the NKG2D receptor in natural killer cells and impairs NKG2D-mediated functions. Haematologica. 2012; 97(9): 1295-1303.

[137] Ochoa AC, Zea AH, Hernandez C, et al. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res. 2007; 13(2): 721s-726s. Pt 2.

[138] Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009; 9(3): 162-174.

[139] Ye L, Zhang Q, Cheng Y, et al. Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1+ regulatory B cell expansion. J Immunother Cancer. 2018; 6(1): 145.

[140] Li G, Chen W, Jiang K, et al. Exosome-mediated delivery of miR-519e-5p promotes malignant tumor phenotype and CD8+ T-cell exhaustion in metastatic PTC. J Clin Endocrinol Metab. 2024; 109(6): 1601-1617.

[141] Hu Z, Chen G, Zhao Y, et al. Exosome-derived circCCAR1 promotes CD8 + T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma. Mol Cancer. 2023; 22(1): 55.

[142] Zeng Y, Hu S, Luo Y, He K. Exosome cargos as biomarkers for diagnosis and prognosis of hepatocellular carcinoma. Pharmaceutics. 2023; 15(9): 2365.

[143] Chalmin F, Ladoire S, Mignot G, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest. 2010; 120(2): 457-471.

[144] Valenti R, Huber V, Filipazzi P, et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res. 2006; 66(18): 9290-9298.

[145] Nawaz M, Shah N, Zanetti BR, et al. Extracellular vesicles and matrix remodeling enzymes: the emerging roles in extracellular matrix remodeling, progression of diseases and tissue repair. Cells. 2018; 7(10): 167.

[146] Webber J, Steadman R, Mason MD, et al. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 2010; 70(23): 9621-9630.

[147] Huang Q, Hsueh CY, Shen YJ, et al. Small extracellular vesicle-packaged TGFβ1 promotes the reprogramming of normal fibroblasts into cancer-associated fibroblasts by regulating fibronectin in head and neck squamous cell carcinoma. Cancer Lett. 2021; 517: 1-13.

[148] Naito Y, Yoshioka Y, Ochiya T. Intercellular crosstalk between cancer cells and cancer-associated fibroblasts via extracellular vesicles. Cancer Cell Int. 2022; 22: 367.

[149] Pérez M, Avila J, Hernández F. Propagation of Tau via extracellular vesicles. Front Neurosci. 2019; 13: 698.

[150] Gomes P, Tzouanou F, Skolariki K, et al. Extracellular vesicles and Alzheimer’s disease in the novel era of precision medicine: implications for disease progression, diagnosis and treatment. Exp Neurol. 2022; 358: 114183.

[151] Si XL, Fang YJ, Li LF, et al. From inflammasome to Parkinson’s disease: does the NLRP3 inflammasome facilitate exosome secretion and exosomal alpha-synuclein transmission in Parkinson’s disease? Exp Neurol. 2021; 336: 113525.

[152] Manna I, Quattrone A, De Benedittis S, et al. Exosomal miRNA as peripheral biomarkers in Parkinson’s disease and progressive supranuclear palsy: a pilot study. Parkinsonism Relat Disord. 2021; 93: 77-84.

[153] Yu H, Sun T, An J, et al. Potential roles of exosomes in Parkinson’s disease: from pathogenesis, diagnosis, and treatment to prognosis. Front Cell Dev Biol. 2020; 8: 86.

[154] Yin Z, Han Z, Hu T, et al. Neuron-derived exosomes with high miR-21-5p expression promoted polarization of M1 microglia in culture. Brain Behav Immun. 2020; 83: 270-282.

[155] Ucci FM, Recalchi S, Barbati C, et al. Citrullinated and carbamylated proteins in extracellular microvesicles from plasma of patients with rheumatoid arthritis. Rheumatology (Oxford). 2023; 62(6): 2312-2319.

[156] Chen R, Zhou D, Chen Y, Chen M, Shuai Z. Understanding the role of exosomal lncRNAs in rheumatic diseases: a review. PeerJ. 2023; 11: e16434.

[157] Ohl K, Tenbrock K. Inflammatory cytokines in systemic lupus erythematosus. J Biomed Biotechnol. 2011; 2011: 432595.

[158] Alivernini S, Gremese E, McSharry C, et al. MicroRNA-155-at the critical interface of innate and adaptive immunity in arthritis. Front Immunol. 2017; 8: 1932.

[159] Takamura Y, Aoki W, Satomura A, et al. Small RNAs detected in exosomes derived from the MH7A synovial fibroblast cell line with TNF-α stimulation. PLoS One. 2018; 13(8): e0201851.

[160] Neves KB, Rios FJ, Sevilla-Montero J, et al. Exosomes and the cardiovascular system: role in cardiovascular health and disease. J Physiol. 2023; 601(22): 4923-4936.

[161] Miaomiao S, Xiaoqian W, Yuwei S, et al. Cancer-associated fibroblast-derived exosome microRNA-21 promotes angiogenesis in multiple myeloma. Sci Rep. 2023; 13(1): 9671.

[162] Olejarz W, Kubiak-Tomaszewska G, Chrzanowska A, et al. Exosomes in angiogenesis and anti-angiogenic therapy in cancers. Int J Mol Sci. 2020; 21(16): 5840.

[163] Tang R, Zhang Z, Xu J, et al. Integration of single-nucleus and exosome RNA sequencing dissected inter-cellular communication and biomarkers in pancreatic ductal adenocarcinoma. Comput Struct Biotechnol J. 2024; 23: 1689-1704.

[164] Wang T, Zhu H, Xiao M, Zhou S. Serum exosomal long noncoding RNA CRNDE as a prognostic biomarker for hepatocellular carcinoma. J Clin Lab Anal. 2021; 35(11): e23959.

[165] Zhu Z, Chen Z, Wang M, et al. Detection of plasma exosomal miRNA-205 as a biomarker for early diagnosis and an adjuvant indicator of ovarian cancer staging. J Ovarian Res. 2022; 15(1): 27.

[166] Jeon H, Seo SM, Kim TW, et al. Circulating exosomal miR-1290 for diagnosis of epithelial ovarian cancer. Curr Issues Mol Biol. 2022; 44(1): 288-300.

[167] Li H, Sui T, Chen X, et al. Screening and identification of serum exosomal protein ZNF587B in liquid biopsy for ovarian cancer diagnosis. Am J Cancer Res. 2024; 14(4): 1904-1913.

[168] Chen J, Wang H, Xu J, et al. CircZFR promotes colorectal cancer progression via stabilizing BCLAF1 and regulating the miR-3127-5p/RTKN2 axis. Sci China Life Sci. 2024. Published online May 24.

[169] Wu Y, Zhang J, Lin F, et al. Exosomal miR-1470 is a diagnostic biomarker and promotes cell proliferation and metastasis in colorectal cancer. Cancer Med. 2024; 13(7): e7117.

[170] Chen Z, Ma X, Chen Z, et al. Exosome-transported circ_0061407 and circ_0008103 play a tumour-repressive role and show diagnostic value in non-small-cell lung cancer. J Transl Med. 2024; 22(1): 427.

[171] Wen N, Peng D, Xiong X, et al. Cholangiocarcinoma combined with biliary obstruction: an exosomal circRNA signature for diagnosis and early recurrence monitoring. Signal Transduct Target Ther. 2024; 9(1): 107.

[172] Sun Z, Wang L, Wu S, et al. An electrochemical biosensor designed by using Zr-based metal-organic frameworks for the detection of glioblastoma-derived exosomes with practical application. Anal Chem. 2020; 92(5): 3819-3826.

[173] Yang P, Lei H, Fu Y, et al. Exosomal miR-151-3p in saliva: a potential non-invasive marker for gastric cancer diagnosis and prognosis modulated by Sijunzi decoction (SJZD) in mice. Heliyon. 2024; 10(7): e29169.

[174] Wang H, He D, Wan K, et al. In situ multiplex detection of serum exosomal microRNAs using an all-in-one biosensor for breast cancer diagnosis. Analyst. 2020; 145(9): 3289-3296.

[175] Zhang Q, Zhao Y, Luo Y, et al. Urinary exosomal miRNA-451a can be used as a potential noninvasive biomarker for diagnosis, reflecting tubulointerstitial damage and therapeutic response in IgA nephropathy. Ren Fail. 2024; 46(1): 2319326.

[176] Sun S, Liang L, Tian R, et al. LncRNA expression profiling in exosomes derived from synovial fluid of patients with rheumatoid arthritis. Int Immunopharmacol. 2024; 130: 111735.

[177] Gan W, Song W, Gao Y, et al. Exosomal circRNAs in the plasma serve as novel biomarkers for IPF diagnosis and progression prediction. J Transl Med. 2024; 22(1): 264.

[178] Tan L, Zhao M, Wu H, et al. Downregulated serum exosomal miR-451a expression correlates with renal damage and its intercellular communication role in systemic lupus erythematosus. Front Immunol. 2021; 12: 630112.

[179] Liu X, Zhang Y, Yuan W, et al. Exosomal circRNAs in circulation serve as diagnostic biomarkers for acute myocardial infarction. Front Biosci (Landmark Ed). 2024; 29(4): 149.

[180] Sanganalmath SK, Dubey S, Veeranki S, et al. The interplay of inflammation, exosomes and Ca2+ dynamics in diabetic cardiomyopathy. Cardiovasc Diabetol. 2023; 22(1): 37.

[181] Zhang W, Cui J, Li L, et al. Identification of plasma exosomes hsa_circ_0001360 and hsa_circ_0000038 as key biomarkers of coronary heart disease. Cardiol Res Pract. 2024; 2024: 5557143.

[182] Duan X, Zheng Q, Liang L, et al. Serum exosomal miRNA-125b and miRNA-451a are potential diagnostic biomarker for Alzheimer’s diseases. Degener Neurol Neuromuscul Dis. 2024; 14: 21-31.

[183] Abrishamdar M, Jalali MS, Yazdanfar N. The role of exosomes in pathogenesis and the therapeutic efficacy of mesenchymal stem cell-derived exosomes against Parkinson’s disease. Neurol Sci. 2023; 44(7): 2277-2289.

[184] Yao YF, Qu MW, Li GC, et al. Circulating exosomal miRNAs as diagnostic biomarkers in Parkinson’s disease. Eur Rev Med Pharmacol Sci. 2018; 22(16): 5278-5283.

[185] Patel N, Chin DD, Chung EJ. Exosomes in atherosclerosis, a double-edged sword: their role in disease pathogenesis and their potential as novel therapeutics. AAPS J. 2021; 23(5): 95.

[186] Carranza C, Herrera MT, Guzmán-Beltrán S, et al. A dual marker for monitoring MDR-TB treatment: host-derived miRNAs and M. tuberculosis-derived RNA sequences in serum. Front Immunol. 2021; 12: 760468.

[187] Hernández-Walias F, Ruiz-de-León MJ, Rosado-Sánchez I, et al. New signatures of poor CD4 cell recovery after suppressive antiretroviral therapy in HIV-1-infected individuals: involvement of miR-192, IL-6, sCD14 and miR-144. Sci Rep. 2020; 10(1): 2937.

[188] Hinestrosa JP, Kurzrock R, Lewis JM, et al. Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test. Commun Med (Lond). 2022; 2: 29.

[189] Jiang C, Zhang N, Hu X, Wang H. Tumor-associated exosomes promote lung cancer metastasis through multiple mechanisms. Mol Cancer. 2021; 20: 117.

[190] Thind A, Wilson C. Exosomal miRNAs as cancer biomarkers and therapeutic targets. J Extracell Vesicles. 2016; 5: 31292.

[191] Jafari A, Karimabadi K, Rahimi A, et al. The emerging role of exosomal miRNAs as biomarkers for early cancer detection: a comprehensive literature review. Technol Cancer Res Treat. 2023; 22: 15330338231205999.

[192] Khan S, Jutzy JMS, Valenzuela MMA, et al. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS One. 2012; 7(10): e46737.

[193] Gheytanchi E, Tajik F, Razmi M, et al. Circulating exosomal microRNAs as potential prognostic biomarkers in gastrointestinal cancers: a systematic review and meta-analysis. Cancer Cell Int. 2023; 23(1): 10.

[194] Saleh AA, Soliman SE, Habib MSED, et al. Potential value of circulatory microRNA122 gene expression as a prognostic and metastatic prediction marker for breast cancer. Mol Biol Rep. 2019; 46(3): 2809-2818.

[195] Luo L, Yang R, Zhao S, et al. Decreased miR-320 expression is associated with breast cancer progression, cell migration, and invasiveness via targeting Aquaporin 1. Acta Biochim Biophys Sin (Shanghai). 2018; 50(5): 473-480.

[196] Gu Z, Yin H, Zhang H, et al. Optimization of a method for the clinical detection of serum exosomal miR-940 as a potential biomarker of breast cancer. Front Oncol. 2022; 12: 956167.

[197] Lan F, Qing Q, Pan Q, et al. Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma. Cell Oncol (Dordr). 2018; 41(1): 25-33.

[198] Duan Y, Zhou M, Ye B, et al. Hypoxia-induced miR-5100 promotes exosome-mediated activation of cancer-associated fibroblasts and metastasis of head and neck squamous cell carcinoma. Cell Death Dis. 2024; 15(3): 215.

[199] Shen Y, Li M, Liao L, et al. Plasma exosome-derived connexin43 as a promising biomarker for melanoma patients. BMC Cancer. 2023; 23: 242.

[200] Bao Y, Xu S, Zhou J, et al. Exosomal miR-93 derived from hepatocellular carcinoma cell promotes the sorafenib resistance of hepatocellular carcinoma through PTEN/PI3K/Akt pathway. J Biochem Mol Toxicol. 2024; 38(3): e23666.

[201] Li K, Lin H, Liu A, et al. SOD1-high fibroblasts derived exosomal miR-3960 promotes cisplatin resistance in triple-negative breast cancer by suppressing BRSK2-mediated phosphorylation of PIMREG. Cancer Lett. 2024; 590: 216842.

[202] Si Q, Wu L, Pang D, Jiang P. Exosomes in brain diseases: pathogenesis and therapeutic targets. MedComm. 2023; 4(3): e287.

[203] Jia L, Qiu Q, Zhang H, et al. Concordance between the assessment of Aβ42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid. Alzheimers Dement. 2019; 15(8): 1071-1080.

[204] Sun B, Dalvi P, Abadjian L, et al. Blood neuron-derived exosomes as biomarkers of cognitive impairment in HIV. AIDS. 2017; 31(14): F9-F17.

[205] Sharma V, Nikolajeff F, Kumar S. Employing nanoparticle tracking analysis of salivary neuronal exosomes for early detection of neurodegenerative diseases. Transl Neurodegener. 2023; 12: 7.

[206] Fiandaca MS, Kapogiannis D, Mapstone M, et al. Identification of pre-clinical Alzheimer’s disease by a profile of pathogenic proteins in neurally-derived blood exosomes: a case-control study. Alzheimers Dement. 2015; 11(6): 600-607. e1.

[207] Jia L, Zhu M, Kong C, et al. Blood neuro-exosomal synaptic proteins predict Alzheimer’s disease at the asymptomatic stage. Alzheimers Dement. 2021; 17(1): 49-60.

[208] Kluge A, Bunk J, Schaeffer E, et al. Detection of neuron-derived pathological α-synuclein in blood. Brain. 2022; 145(9): 3058-3071.

[209] Yan S, Jiang C, Janzen A, et al. Neuronally derived extracellular vesicle α-synuclein as a serum biomarker for individuals at risk of developing Parkinson disease. JAMA Neurol. 2024; 81(1): 59-68.

[210] Mattingly J, Li Y, Bihl JC, et al. The promise of exosome applications in treating central nervous system diseases. CNS Neurosci Ther. 2021; 27(12): 1437-1445.

[211] Goetzl EJ, Abner EL, Jicha GA, et al. Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer’s disease. FASEB J. 2018; 32(2): 888-893.

[212] Long J, Zhang Y, Liu X, et al. Exosomes in the field of neuroscience: a scientometric study and visualization analysis. Front Neurol. 2022; 13: 871491.

[213] Wang Y, Liu Y, Jin Z, et al. Association between mitochondrial function and rehabilitation of Parkinson’s disease: revealed by exosomal mRNA and lncRNA expression profiles. Front Aging Neurosci. 2022; 14: 909622.

[214] Zhang Z, Zou Y, Song C, et al. Advances in the study of exosomes in cardiovascular diseases. J Adv Res. 2023:S2090123223004022. Published online December.

[215] Jung SE, Kim SW, Choi JW. Exploring cardiac exosomal RNAs of acute myocardial infarction. Biomedicines. 2024; 12(2): 430.

[216] Eshraghi R, Rafiei M, Hadian Jazi Z, et al. MicroRNA-155 and exosomal microRNA-155: small pieces in the cardiovascular diseases puzzle. Pathol Res Pract. 2024; 257: 155274.

[217] D’Alessandra Y, Devanna P, Limana F, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J. 2010; 31(22): 2765-2773.

[218] Liang C, Zhang L, Lian X, et al. Circulating exosomal SOCS2-AS1 acts as a novel biomarker in predicting the diagnosis of coronary artery disease. Biomed Res Int. 2020; 2020: 9182091.

[219] Zhang P, Liang T, Chen Y, et al. Circulating exosomal miRNAs as novel biomarkers for stable coronary artery disease. Biomed Res Int. 2020; 2020: 3593962.

[220] Li Q, Feng Q, Zhou H, et al. Mechanisms and therapeutic strategies of extracellular vesicles in cardiovascular diseases. MedComm. 2023; 4(6): e454.

[221] Matsumoto S, Sakata Y, Suna S, et al. Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction. Circ Res. 2013; 113(3): 322-326.

[222] Zhou R, Wang L, Zhao G, et al. Circulating exosomal microRNAs as emerging non-invasive clinical biomarkers in heart failure: mega bio-roles of a nano bio-particle. IUBMB Life. 2020; 72(12): 2546-2562.

[223] Yao Y, Song T, Xiong G, et al. Combination of peripheral blood mononuclear cell miR-19b-5p, miR-221, miR-25-5p, and hypertension correlates with an increased heart failure risk in coronary heart disease patients. Anatol J Cardiol. 2018; 20(2): 100-109.

[224] Ji M, Wei Y, Ye Z, et al. In vivo fluorescent labeling of foam cell-derived extracellular vesicles as circulating biomarkers for in vitro detection of atherosclerosis. J Am Chem Soc. 2024; 146(14): 10093-10102.

[225] Jin X, Xu W, Wu Q, et al. Detecting early-warning biomarkers associated with heart-exosome genetic-signature for acute myocardial infarction: a source-tracking study of exosome. J Cell Mol Med. 2024; 28(8): e18334.

[226] Li W, Li Y, Zhi W, et al. Diagnostic value of using exosome-derived cysteine-rich protein 61 as biomarkers for acute coronary syndrome. Exp Ther Med. 2021; 22(6): 1437.

[227] Sharma P, Roy A, Dhamija RK, et al. A comprehensive proteomic profiling of urinary exosomes and the identification of early non-invasive biomarker in patients with coronary artery disease. J Proteom. 2024; 293: 105059.

[228] Tsai PC, Ko AMS, Chen YL, et al. Exosomal miRNA changes associated with restoration to sinus rhythm in atrial fibrillation patients. Int J Mol Sci. 2024; 25(7): 3861.

[229] Yarana C, Carroll D, Chen J, et al. Extracellular vesicles released by cardiomyocytes in a doxorubicin-induced cardiac injury mouse model contain protein biomarkers of early cardiac injury. Clin Cancer Res. 2018; 24(7): 1644-1653.

[230] Anel A, Gallego-Lleyda A, de Miguel D, et al. Role of exosomes in the regulation of T-cell mediated immune responses and in autoimmune disease. Cells. 2019; 8(2): 154.

[231] Mukhamedova N, Hoang A, Dragoljevic D, et al. Exosomes containing HIV protein Nef reorganize lipid rafts potentiating inflammatory response in bystander cells. PLoS Pathog. 2019; 15(7): e1007907.

[232] Hubert A, Subra C, Jenabian MA, et al. Elevated abundance, size, and MicroRNA content of plasma extracellular vesicles in viremic HIV-1+ patients: correlations with known markers of disease progression. J Acquir Immune Defic Syndr. 2015; 70(3): 219-227.

[233] Qiu Y, Ma J, Zeng Y. Therapeutic potential of anti-HIV RNA-loaded exosomes. Biomed Environ Sci. 2018; 31(3): 215-226.

[234] Haque S, Kodidela S, Gerth K, et al. Extracellular vesicles in smoking-mediated HIV pathogenesis and their potential role in biomarker discovery and therapeutic interventions. Cells. 2020; 9(4): 864.

[235] Hu G, Yelamanchili S, Kashanchi F, et al. Proceedings of the 2017 ISEV symposium on “HIV, NeuroHIV, drug abuse, & EVs”. J Neurovirol. 2017; 23(6): 935-940.

[236] Gorgzadeh A, Nazari A, Ali Ehsan Ismaeel A, et al. A state-of-the-art review of the recent advances in exosome isolation and detection methods in viral infection. Virol J. 2024; 21: 34.

[237] Kodidela S, Wang Y, Patters BJ, et al. Proteomic profiling of exosomes derived from plasma of HIV-infected alcohol drinkers and cigarette smokers. J Neuroimmune Pharmacol. 2020; 15(3): 501-519.

[238] Dimov I, Jankovic Velickovic L, Stefanovic V. Urinary exosomes. ScientificWorldJournal. 2009; 9: 1107-1118.

[239] Sukriti S, Choudhary MC, Maras JS, et al. Extracellular vesicles from hepatitis B patients serve as reservoir of hepatitis B virus DNA. J Viral Hepat. 2019; 26(1): 211-214.

[240] Xu X, Zhang L, Liu J, et al. Exosomal HBV-DNA for diagnosis and treatment monitoring of chronic hepatitis B. Open Life Sci. 2023; 18(1): 20220585.

[241] Sinha A, Yadav AK, Chakraborty S, et al. Exosome-enclosed microRNAs in exhaled breath hold potential for biomarker discovery in patients with pulmonary diseases. J Allergy Clin Immunol. 2013; 132(1): 219-222.

[242] Wang Y, Xu YM, Zou YQ, et al. Identification of differential expressed PE exosomal miRNA in lung adenocarcinoma, tuberculosis, and other benign lesions. Medicine (Baltimore). 2017; 96(44): e8361.

[243] Lv L, Li C, Zhang X, et al. RNA profiling analysis of the serum exosomes derived from patients with active and latent Mycobacterium tuberculosis infection. Front Microbiol. 2017; 8: 1051.

[244] Balbi C, Burrello J, Bolis S, et al. Circulating extracellular vesicles are endowed with enhanced procoagulant activity in SARS-CoV-2 infection. EBioMedicine. 2021; 67: 103369.

[245] Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020; 181(7): 1489-1501. e15.

[246] Barberis E, Vanella VV, Falasca M, et al. Circulating exosomes are strongly involved in SARS-CoV-2 infection. Front Mol Biosci. 2021; 8: 632290.

[247] Lee JY, Park JK, Lee EY, et al. Circulating exosomes from patients with systemic lupus erythematosus induce an proinflammatory immune response. Arthritis Res Ther. 2016; 18(1): 264.

[248] Li W, Liu S, Chen Y, et al. Circulating exosomal microRNAs as biomarkers of systemic lupus erythematosus. Clinics (Sao Paulo). 2020; 75: e1528.

[249] Perez-Hernandez J, Forner MJ, Pinto C, et al. Increased urinary exosomal microRNAs in patients with systemic lupus erythematosus. PloS One. 2015; 10(9): e0138618.[crossref]

[250] Perez-Hernandez J, Martinez-Arroyo O, Ortega A, et al. Urinary exosomal miR-146a as a marker of albuminuria, activity changes and disease flares in lupus nephritis. J Nephrol. 2021; 34(4): 1157-1167.

[251] Solé C, Cortés-Hernández J, Felip ML, et al. miR-29c in urinary exosomes as predictor of early renal fibrosis in lupus nephritis. Nephrol Dial Transplant. 2015; 30(9): 1488-1496.

[252] Ichii O, Otsuka-Kanazawa S, Horino T, et al. Decreased miR-26a expression correlates with the progression of podocyte injury in autoimmune glomerulonephritis. PLoS One. 2014; 9(10): e110383.

[253] Garcia-Vives E, Solé C, Moliné T, et al. The urinary exosomal miRNA expression profile is predictive of clinical response in lupus nephritis. Int J Mol Sci. 2020; 21(4): 1372.

[254] Yu Y, Park S, Lee H, et al. Exosomal hsa-miR-335-5p and hsa-miR-483-5p are novel biomarkers for rheumatoid arthritis: a development and validation study. Int Immunopharmacol. 2023; 120: 110286.

[255] Rodríguez-Muguruza S, Altuna-Coy A, Castro-Oreiro S, et al. A serum biomarker panel of exomiR-451a, exomiR-25-3p and soluble TWEAK for early diagnosis of rheumatoid arthritis. Front Immunol. 2021; 12: 790880.

[256] Yang X, Wang Z, Zhang M, et al. Differential expression profiles of plasma exosomal microRNAs in rheumatoid arthritis. J Inflamm Res. 2023; 16: 3687-3698.

[257] Huang L, Liang L, Ji Z, et al. Proteomics profiling of CD4 + T-cell-derived exosomes from patients with rheumatoid arthritis. Int Immunopharmacol. 2023; 122: 110560.

[258] Zq S, Zx W, Jl R, et al. Differential expressions and potential clinical values of lncRNAs in the plasma exosomes of rheumatoid arthritis. Int Immunopharmacol. 2024; 128: 111511.

[259] Song J, Kim D, Han J, et al. PBMC and exosome-derived Hotair is a critical regulator and potent marker for rheumatoid arthritis. Clin Exp Med. 2015; 15(1): 121-126.

[260] Wang Y, Zheng F, Gao G, et al. MiR-548a-3p regulates inflammatory response via TLR4/NF-κB signaling pathway in rheumatoid arthritis. J Cell Biochem. 2019; 120(2): 1133-1140.

[261] Liao TL, Chen IC, Chen HW, et al. Exosomal microRNAs as biomarkers for viral replication in tofacitinib-treated rheumatoid arthritis patients with hepatitis C. Sci Rep. 2024; 14(1): 937.

[262] Welton JL, Loveless S, et al. Cerebrospinal fluid extracellular vesicle enrichment for protein biomarker discovery in neurological disease; multiple sclerosis. J Extracell Vesicles. 2017; 6(1): 1369805.

[263] Kimura K, Hohjoh H, Fukuoka M, et al. Circulating exosomes suppress the induction of regulatory T cells via let-7i in multiple sclerosis. Nat Commun. 2018; 9(1): 17.

[264] Selmaj I, Cichalewska M, Namiecinska M, et al. Global exosome transcriptome profiling reveals biomarkers for multiple sclerosis. Ann Neurol. 2017; 81(5): 703-717.

[265] Lee J, McKinney KQ, Pavlopoulos AJ, et al. Exosomal proteome analysis of cerebrospinal fluid detects biosignatures of neuromyelitis optica and multiple sclerosis. Clin Chim Acta. 2016; 462: 118-126.

[266] Galazka G, Mycko MP, Selmaj I, et al. Multiple sclerosis: serum-derived exosomes express myelin proteins. Mult Scler. 2018; 24(4): 449-458.

[267] Torres Iglesias G, Fernández-Fournier M, Botella L, et al. Brain and immune system-derived extracellular vesicles mediate regulation of complement system, extracellular matrix remodeling, brain repair and antigen tolerance in multiple sclerosis. Brain Behav Immun. 2023; 113: 44-55.

[268] Honardoost MA, Kiani-Esfahani A, Ghaedi K, et al. miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis. Gene. 2014; 544(2): 128-133.

[269] Ebrahimkhani S, Vafaee F, Young PE, et al. Exosomal microRNA signatures in multiple sclerosis reflect disease status. Sci Rep. 2017; 7(1): 14293.

[270] Nali LH, Fink MC, do Olival GS, et al. Polyomavirus detection in multiple sclerosis patients under natalizumab therapy: profile and frequency of urinary shedding. J Med Virol. 2017; 89(3): 528-534.

[271] Kakan SS, Janga SR, Cooperman B, et al. Small RNA deep sequencing identifies a unique miRNA Signature released in serum exosomes in a mouse model of Sjögren’s Syndrome. Front Immunol. 2020; 11: 1475.

[272] Zhang R, Wei Y, Wang T, et al. Exosomal miRNAs in autoimmune skin diseases. Front Immunol. 2023; 14: 1307455.

[273] Yoon SY, Kim JS, Jung SW, et al. Clinical significance of urinary exosomal microRNAs in patients with IgA nephropathy. Sci Rep. 2023; 13(1): 17201.

[274] Mu Y, Huang X, Yang Y, et al. Study of serum exosome miRNA as a biomarker for early onset adult ouclar myastthenia gravis. Gene. 2024; 896: 148034.

[275] Zheng X, Chen F, Zhang Q, et al. Salivary exosomal PSMA7: a promising biomarker of inflammatory bowel disease. Protein Cell. 2017; 8(9): 686-695.

[276] Wu F, Guo NJ, Tian H, et al. Peripheral blood microRNAs distinguish active ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis. 2011; 17(1): 241-250.

[277] Shan Y, Hou B, Wang J, et al. Exploring the role of exosomal MicroRNAs as potential biomarkers in preeclampsia. Front Immunol. 2024; 15: 1385950.

[278] Arora S, Verma N. Exosomal microRNAs as potential biomarkers and therapeutic targets in corneal diseases. Mol Vis. 2024; 30: 92-106.

[279] Pan W, Li S, Li K, et al. Mesenchymal stem cells and extracellular vesicles: therapeutic potential in organ transplantation. Stem Cells Int. 2024; 2024: 2043550.

[280] Fuentes-Baile M, Pérez-Valenciano E, García-Morales P, et al. CLytA-DAAO chimeric enzyme bound to magnetic nanoparticles. A new therapeutical approach for cancer patients? Int J Mol Sci. 2021; 22(3): 1477.

[281] Fuentes-Baile M, García-Morales P, Pérez-Valenciano E, et al. Cell death mechanisms induced by CLytA-DAAO chimeric enzyme in human tumor cell lines. Int J Mol Sci. 2020; 21(22): 8522.

[282] Mitchell MJ, Billingsley MM, Haley RM, et al. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021; 20(2): 101-124.

[283] Sen S, Xavier J, Kumar N, et al. Exosomes as natural nanocarrier-based drug delivery system: recent insights and future perspectives. 3 Biotech. 2023; 13(3): 101.

[284] Yang T, Martin P, Fogarty B, et al. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. Pharm Res. 2015; 32(6): 2003-2014.

[285] Qu M, Lin Q, Huang L, et al. Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson’s disease. J Control Release. 2018; 287: 156-166.

[286] Hadla M, Palazzolo S, Corona G, et al. Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models. Nanomedicine (Lond). 2016; 11(18): 2431-2441.

[287] Kalimuthu S, Gangadaran P, Rajendran RL, et al. A new approach for loading anticancer drugs into mesenchymal stem cell-derived exosome mimetics for cancer therapy. Front Pharmacol. 2018; 9: 1116.

[288] Pascucci L, Coccè V, Bonomi A, et al. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. J Control Release. 2014; 192: 262-270.

[289] Zhang X, Liu L, Tang M, et al. The effects of umbilical cord-derived macrophage exosomes loaded with cisplatin on the growth and drug resistance of ovarian cancer cells. Drug Dev Ind Pharm. 2020; 46(7): 1150-1162.

[290] Li YJ, Wu JY, Wang JM, et al. Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer. Acta Biomater. 2020; 101: 519-530.

[291] Sun D, Zhuang X, Xiang X, et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther. 2010; 18(9): 1606-1614.

[292] Taravat M, Asadpour R, Jafari Jozani R, et al. Engineered exosome as a biological nanoplatform for drug delivery of Rosmarinic acid to improve implantation in mice with induced endometritis. Syst Biol Reprod Med. 2024; 70(1): 3-19.

[293] Zhu ZH, Jia F, Ahmed W, et al. Neural stem cell-derived exosome as a nano-sized carrier for BDNF delivery to a rat model of ischemic stroke. Neural Regen Res. 2023; 18(2): 404-409.

[294] Arrè V, Mastrogiacomo R, Balestra F, et al. Unveiling the potential of extracellular vesicles as biomarkers and therapeutic nanotools for gastrointestinal diseases. Pharmaceutics. 2024; 16(4): 567.

[295] Wang B, Zhuang X, Deng ZB, et al. Targeted drug delivery to intestinal macrophages by bioactive nanovesicles released from grapefruit. Mol Ther. 2014; 22(3): 522-534.

[296] Munagala R, Aqil F, Jeyabalan J, et al. Exosomal formulation of anthocyanidins against multiple cancer types. Cancer Lett. 2017; 393: 94-102.

[297] Kumar DN, Chaudhuri A, Dehari D, et al. Enhanced therapeutic efficacy against melanoma through exosomal delivery of hesperidin. Mol Pharm. 2024; 21(6): 3061-3076.

[298] Barok M, Puhka M, Vereb G, et al. Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation. BMC Cancer. 2018; 18: 504.

[299] Luan X, Sansanaphongpricha K, Myers I, et al. Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol Sin. 2017; 38(6): 754-763.

[300] Sadeghi S, Tehrani FR, Tahmasebi S, et al. Exosome engineering in cell therapy and drug delivery. Inflammopharmacology. 2023; 31(1): 145-169.

[301] Nan W, Zhang C, Wang H, et al. Direct modification of extracellular vesicles and its applications for cancer therapy: a mini-review. Front Chem. 2022; 10: 910341.

[302] Chen H, Wang L, Zeng X, et al. Exosomes, a new star for targeted delivery. Front Cell Dev Biol. 2021; 9: 751079.

[303] Liang SF, Zuo FF, Yin BC, et al. Delivery of siRNA based on engineered exosomes for glioblastoma therapy by targeting STAT3. Biomater Sci. 2022; 10(6): 1582-1590.

[304] Zhang Z, Luo X, Xue X, et al. Engineered exosomes carrying miR-588 for treatment of triple negative breast cancer through remodeling the immunosuppressive microenvironment. Int J Nanomed. 2024; 19: 743-758.

[305] Jayasinghe MK, Pirisinu M, Yang Y, et al. Surface-engineered extracellular vesicles for targeted delivery of therapeutic RNAs and peptides for cancer therapy. Theranostics. 2022; 12(7): 3288-3315.

[306] Kim MS, Haney MJ, Zhao Y, et al. Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations. Nanomedicine. 2018; 14(1): 195-204.

[307] Li S, Wu Y, Ding F, et al. Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancer. Nanoscale. 2020; 12(19): 10854-10862.

[308] Nguyen Cao TG, Kang JH, You JY, et al. Safe and targeted sonodynamic cancer therapy using biocompatible exosome-based nanosonosensitizers. ACS Appl Mater Interfaces. 2021; 13(22): 25575-25588.

[309] Tian T, Liang R, Erel-Akbaba G, et al. Immune checkpoint inhibition in GBM primed with radiation by engineered extracellular vesicles. ACS Nano. 2022; 16(2): 1940-1953.

[310] Liang G, Zhu Y, Ali DJ, et al. Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer. J Nanobiotechnol. 2020; 18(1): 10.

[311] Xu X, Liang Y, Li X, et al. Exosome-mediated delivery of kartogenin for chondrogenesis of synovial fluid-derived mesenchymal stem cells and cartilage regeneration. Biomaterials. 2021; 269: 120539.

[312] Tian T, Zhang HX, He CP, et al. Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. Biomaterials. 2018; 150: 137-149.

[313] Jia G, Han Y, An Y, et al. NRP-1 targeted and cargo-loaded exosomes facilitate simultaneous imaging and therapy of glioma in vitro and in vivo. Biomaterials. 2018; 178: 302-316.

[314] Malekian F, Shamsian A, et al. Exosome engineering for efficient and targeted drug delivery: current status and future perspective. J Physiol. 2023; 601(22): 4853-4872.

[315] Liu Q, Li D, Pan X, et al. Targeted therapy using engineered extracellular vesicles: principles and strategies for membrane modification. J Nanobiotechnol. 2023; 21(1): 334.

[316] Zhang H, Wu J, Wu J, et al. Exosome-mediated targeted delivery of miR-210 for angiogenic therapy after cerebral ischemia in mice. J Nanobiotechnol. 2019; 17: 29.

[317] Qi H, Liu C, Long L, et al. Blood exosomes endowed with magnetic and targeting properties for cancer therapy. ACS Nano. 2016; 10(3): 3323-3333.

[318] Vandergriff A, Huang K, Shen D, et al. Targeting regenerative exosomes to myocardial infarction using cardiac homing peptide. Theranostics. 2018; 8(7): 1869-1878.

[319] Pham TC, Jayasinghe MK, Pham TT, et al. Covalent conjugation of extracellular vesicles with peptides and nanobodies for targeted therapeutic delivery. J Extracell Vesicles. 2021; 10(4): e12057.

[320] Liang Y, Duan L, Lu J, et al. Engineering exosomes for targeted drug delivery. Theranostics. 2021; 11(7): 3183-3195.

[321] Alvarez-Erviti L, Seow Y, Yin H, et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011; 29(4): 341-345.

[322] Hung ME, Leonard JN. Stabilization of exosome-targeting peptides via engineered glycosylation. J Biol Chem. 2015; 290(13): 8166-8172.

[323] Tian Y, Li S, Song J, et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 2014; 35(7): 2383-2390.

[324] Zhao Z, Shuang T, Gao Y, et al. Targeted delivery of exosomal miR-484 reprograms tumor vasculature for chemotherapy sensitization. Cancer Lett. 2022; 530: 45-58.

[325] Bai J, Duan J, Liu R, et al. Engineered targeting tLyp-1 exosomes as gene therapy vectors for efficient delivery of siRNA into lung cancer cells. Asian J Pharm Sci. 2020; 15(4): 461-471.

[326] Liang G, Zhu Y, Ali DJ, et al. Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer—PubMed. J Nanobiotechnol. 2020; 18(1): 10.

[327] Bellavia D, Raimondo S, Calabrese G, et al. Interleukin 3-receptor targeted exosomes inhibit in vitro and in vivo chronic myelogenous leukemia cell growth. Theranostics. 2017; 7(5): 1333-1345.

[328] Ohno S, Takanashi M, Sudo K, et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther. 2013; 21(1): 185-191.

[329] Ran N, Gao X, Dong X, et al. Effects of exosome-mediated delivery of myostatin propeptide on functional recovery of mdx mice. Biomaterials. 2020; 236: 119826.

[330] Longatti A, Schindler C, Collinson A, et al. High affinity single-chain variable fragments are specific and versatile targeting motifs for extracellular vesicles. Nanoscale. 2018; 10(29): 14230-14244.

[331] Liang G, Kan S, Zhu Y, et al. Engineered exosome-mediated delivery of functionally active miR-26a and its enhanced suppression effect in HepG2 cells. Int J Nanomed. 2018; 13: 585-599.

[332] Hong Y, Nam G, Koh E, et al. Exosome as a vehicle for delivery of membrane protein therapeutics, PH20, for enhanced tumor penetration and antitumor efficacy. Adv Funct Mater. 2018; 28(5): 1703074.

[333] Huang W, Qu M, Li L, et al. SiRNA in MSC-derived exosomes silences CTGF gene for locomotor recovery in spinal cord injury rats. Stem Cell Res Ther. 2021; 12(1): 334.

[334] Sun M, Zhang H, Liu J, et al. Extracellular vesicles: a new star for gene drug delivery. Int J Nanomed. 2024; 19: 2241-2264.

[335] El-Andaloussi S, Lee Y, Lakhal-Littleton S, et al. Exosome-mediated delivery of siRNA in vitro and in vivo. Nat Protoc. 2012; 7(12): 2112-2126.

[336] Shtam TA, Kovalev RA, Varfolomeeva EY, et al. Exosomes are natural carriers of exogenous siRNA to human cells in vitro. Cell Commun Signal. 2013; 11: 88.

[337] Fitamant J, Kottakis F, Benhamouche S, et al. YAP inhibition restores hepatocyte differentiation in advanced HCC, leading to tumor regression. Cell Rep. 2015; 10(10): 1692-1707.

[338] Zhang Y, Belaid M, Luo X, et al. Probing milk extracellular vesicles for intestinal delivery of RNA therapies. J Nanobiotechnol. 2023; 21: 406.

[339] Zhang H, Yan W, Wang J, et al. Surface functionalization of exosomes for chondrocyte-targeted siRNA delivery and cartilage regeneration. J Control Release. 2024; 369: 493-505.

[340] Yao S, Yin Y, Jin G, et al. Exosome-mediated delivery of miR-204-5p inhibits tumor growth and chemoresistance. Cancer Med. 2020; 9(16): 5989-5998.

[341] Wu H, Fan H, Shou Z, et al. Extracellular vesicles containing miR-146a attenuate experimental colitis by targeting TRAF6 and IRAK1. Int Immunopharmacol. 2019; 68: 204-212.

[342] Yang J, Zhou CZ, Zhu R, et al. miR-200b-containing microvesicles attenuate experimental colitis associated intestinal fibrosis by inhibiting epithelial-mesenchymal transition. J Gastroenterol Hepatol. 2017; 32(12): 1966-1974.

[343] Mizrak A, Bolukbasi MF, Ozdener GB, et al. Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth. Mol Ther. 2013; 21(1): 101-108.

[344] Haney MJ, Klyachko NL, Zhao Y, et al. Exosomes as drug delivery vehicles for Parkinson’s disease therapy. J Control Release. 2015; 207: 18-30.

[345] Zhang C, Pathrikar TV, Baby HM, et al. Charge-reversed exosomes for targeted gene delivery to cartilage for osteoarthritis treatment. Small Methods. 2024:e2301443. Published online April 12.

[346] You Y, Tian Y, Yang Z, et al. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy. Nat Biomed Eng. 2023; 7(7): 887-900.

[347] Li Z, Zhao P, Zhang Y, et al. Exosome-based Ldlr gene therapy for familial hypercholesterolemia in a mouse model. Theranostics. 2021; 11(6): 2953-2965.

[348] Xu Q, Zhang Z, Zhao L, et al. Tropism-facilitated delivery of CRISPR/Cas9 system with chimeric antigen receptor-extracellular vesicles against B-cell malignancies. J Control Release. 2020; 326: 455-467.

[349] Chen R, Yuan W, Zheng Y, et al. Delivery of engineered extracellular vesicles with miR-29b editing system for muscle atrophy therapy. J Nanobiotechnol. 2022; 20(1): 304.

[350] Cheng Q, Dai Z, Smbatyan G, et al. Eliciting anti-cancer immunity by genetically engineered multifunctional exosomes. Mol Ther. 2022; 30(9): 3066-3077.

[351] Borst J, Ahrends T, Bąbała N, et al. CD4+ T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018; 18(10): 635-647.

[352] Wang X, Xia J, Yang L, et al. Recent progress in exosome research: isolation, characterization and clinical applications. Cancer Gene Ther. 2023; 30(8): 1051-1065.

[353] Munoz JL, Bliss SA, Greco SJ, et al. Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol Ther Nucleic Acids. 2013; 2(10): e126.

[354] Dai S, Zhou X, Wang B, et al. Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8(+) CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells. J Mol Med (Berl). 2006; 84(12): 1067-1076.

[355] Yang Y, Xiu F, Cai Z, et al. Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells. J Cancer Res Clin Oncol. 2007; 133(6): 389-399.

[356] Xiu F, Cai Z, Yang Y, et al. Surface anchorage of superantigen SEA promotes induction of specific antitumor immune response by tumor-derived exosomes. J Mol Med (Berl). 2007; 85(5): 511-521.

[357] Yang F, Wang M, Guan X. Exosomes and mimics as novel delivery platform for cancer therapy. Front Pharmacol. 2022; 13: 1001417.

[358] Pitt JM, André F, Amigorena S, et al. Dendritic cell–derived exosomes for cancer therapy. J Clin Invest. 2016; 126(4): 1224-1232.

[359] Feng H, Zeng Y, Whitesell L, et al. Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. Blood. 2001; 97(11): 3505-3512.

[360] Xiao W, Dong W, Zhang C, et al. Effects of the epigenetic drug MS-275 on the release and function of exosome-related immune molecules in hepatocellular carcinoma cells. Eur J Med Res. 2013; 18(1): 61.

[361] Zhou W, Zhou Y, Chen X, et al. Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials. 2021; 268: 120546.

[362] Fernández-Delgado I, Calzada-Fraile D, Sánchez-Madrid F. Immune regulation by dendritic cell extracellular vesicles in cancer immunotherapy and vaccines. Cancers (Basel). 2020; 12(12): 3558.

[363] Liu C, Liu X, Xiang X, et al. A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy. Nat Nanotechnol. 2022; 17(5): 531-540.

[364] Phung CD, Pham TT, Nguyen HT, et al. Anti-CTLA-4 antibody-functionalized dendritic cell-derived exosomes targeting tumor-draining lymph nodes for effective induction of antitumor T-cell responses. Acta Biomater. 2020; 115: 371-382.

[365] Munich S, Sobo-Vujanovic A, Buchser WJ, et al. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology. 2012; 1(7): 1074-1083.

[366] Hu S, Ma J, Su C, et al. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis. Acta Biomater. 2021; 135: 567-581.

[367] Meng S, Whitt AG, Stamp BF, et al. Exosome-based cancer vaccine for prevention of lung cancer. Stem Cell Investig. 2023; 10: 2.

[368] Yoshioka Y, Kosaka N, Konishi Y, et al. Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen. Nat Commun. 2014; 5: 3591.

[369] McKiernan J, Donovan MJ, O’Neill V, et al. A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. JAMA Oncol. 2016; 2(7): 882-889.

[370] Ge X, Guo M, Li M, et al. Potential blood biomarkers for chronic traumatic encephalopathy: the multi-omics landscape of an observational cohort. Front Aging Neurosci. 2022; 14: 1052765.

[371] Tutrone R, Donovan MJ, Torkler P, et al. Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial biopsy with a PSA 2–10 ng/mL. Prostate Cancer Prostatic Dis. 2020; 23(4): 607-614.

[372] Tutrone R, Lowentritt B, Neuman B, et al. ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer—an interim analysis. Prostate Cancer Prostatic Dis. 2023; 26(3): 596-601.

[373] Nakao Y, Amrollahi P, Parthasarathy G, et al. Circulating extracellular vesicles are a biomarker for NAFLD resolution and response to weight loss surgery. Nanomedicine. 2021; 36: 102430.

[374] Li M, Sun C, Xue S, et al. Complement protein levels in serum astrocyte-derived exosomes are associated with cognitive impairment in obstructive sleep apnea. J Clin Sleep Med. 2023; 19(4): 727-739.

[375] Ng K, Stenzl A, Sharma A, et al. Urinary biomarkers in bladder cancer: a review of the current landscape and future directions. Urol Oncol. 2021; 39(1): 41-51.

[376] Erb U, Zöller M. Progress and potential of exosome analysis for early pancreatic cancer detection. Expert Rev Mol Diagn. 2016; 16(7): 757-767.

[377] Shi J. Considering exosomal miR-21 as a biomarker for cancer. J Clin Med. 2016; 5(4): 42.

[378] Chen L, Cao P, Huang C, et al. Serum exosomal miR-7977 as a novel biomarker for lung adenocarcinoma. J Cell Biochem. 2020; 121(5-6): 3382-3391.

[379] Kobayashi M, Sawada K, Nakamura K, et al. Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types. J Ovarian Res. 2018; 11(1): 81.

[380] Morse MA, Garst J, Osada T, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med. 2005; 3: 9.

[381] Escudier B, Dorval T, Chaput N, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med. 2005; 3: 10.

[382] Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol. 2014; 14(3): 195-208.

[383] Besse B, Charrier M, Lapierre V, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 2016; 5(4): e1071008.

[384] Ma J, Zhang Y, Tang K, et al. Reversing drug resistance of soft tumor-repopulating cells by tumor cell-derived chemotherapeutic microparticles. Cell Res. 2016; 26(6): 713-727.

[385] Guo M, Wu F, Hu G, et al. Autologous tumor cell-derived microparticle-based targeted chemotherapy in lung cancer patients with malignant pleural effusion. Sci Transl Med. 2019; 11(474): eaat5690.

[386] Dong X, Huang Y, Yi T, et al. Intrapleural infusion of tumor cell-derived microparticles packaging methotrexate or saline combined with pemetrexed-cisplatin chemotherapy for the treatment of malignant pleural effusion in advanced non-squamous non-small cell lung cancer: a double-blind, randomized, placebo-controlled study. Front Immunol. 2022; 13: 1002938.

[387] Sengupta V, Sengupta S, Lazo A, et al. Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells Dev. 2020; 29(12): 747-754.

[388] Lightner AL, Sengupta V, Qian S, et al. Bone marrow mesenchymal stem cell-derived extracellular vesicle infusion for the treatment of respiratory failure from COVID-19: a randomized, placebo-controlled dosing clinical trial. Chest. 2023; 164(6): 1444-1453.

[389] Zhu YG, Shi MM, Monsel A, et al. Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19: a pilot study. Stem Cell Res Ther. 2022; 13(1): 220.

[390] Zhou T, He C, Lai P, et al. miR-204-containing exosomes ameliorate GVHD-associated dry eye disease. Sci Adv. 2022; 8(2): eabj9617.

[391] Xie X, Song Q, Dai C, et al. Clinical safety and efficacy of allogenic human adipose mesenchymal stromal cells-derived exosomes in patients with mild to moderate Alzheimer’s disease: a phase I/II clinical trial. Gen Psychiatr. 2023; 36(5): e101143.

[392] Park GH, Kwon HH, Seok J, et al. Efficacy of combined treatment with human adipose tissue stem cell-derived exosome-containing solution and microneedling for facial skin aging: a 12-week prospective, randomized, split-face study. J Cosmet Dermatol. 2023; 22(12): 3418-3426.

[393] Kwon HH, Yang SH, Lee J, et al. Combination treatment with human adipose tissue stem cell-derived exosomes and fractional CO₂ laser for acne scars: a 12-week prospective, double-blind, randomized, split-face study. Acta Derm Venereol. 2020; 100(18): adv00310.

[394] Jin Z, Na J, Lin X, et al. Plant-derived exosome-like nanovesicles: a novel nanotool for disease therapy. Heliyon. 2024; 10(9): e30630.

[395] Salomon C, Guanzon D, Scholz-Romero K, et al. Placental exosomes as early biomarker of preeclampsia: potential role of exosomal microRNAs across gestation. J Clin Endocrinol Metab. 2017; 102(9): 3182-3194.

[396] Pillay P, Moodley K, Moodley J, et al. Placenta-derived exosomes: potential biomarkers of preeclampsia. Int J Nanomed. 2017; 12: 8009-8023.

[397] Colao IL, Corteling R, Bracewell D, et al. Manufacturing exosomes: a promising therapeutic platform. Trends Mol Med. 2018; 24(3): 242-256.

[398] Yang D, Zhang W, Zhang H, et al. Progress, opportunity, and perspective on exosome isolation—efforts for efficient exosome-based theranostics. Theranostics. 2020; 10(8): 3684-3707.

[399] Li B, Kugeratski FG, Kalluri R. A novel machine learning algorithm selects proteome signature to specifically identify cancer exosomes. eLife; 12:RP90390.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.